Becton DickinsonBDX +2.44%76 EBITDA Margin % is 15.02% as of Mar. 2026, which is 34% below its 10-year median of 22.84. GuruFocus rates BDX with a GF Score™ of 76/100 and a GF Value™ of $191.05 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Becton Dickinson ranks better than 79.17% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Becton Dickinson's EBITDA for the
three
months ended in Mar. 2026 was $708 Mil. Becton Dickinson's Revenue for the
three
months ended in Mar. 2026 was $4,714 Mil. Therefore, Becton Dickinson's EBITDA margin for the quarter that ended in Mar. 2026 was 15.02%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Becton Dickinson EBITDA Margin % Related Terms
Becton Dickinson EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Becton Dickinson's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Becton Dickinson's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Becton Dickinson EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Becton Dickinson's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Becton Dickinson's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Becton Dickinson (BDX) has a EBITDA Margin % of 15.02% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Becton Dickinson and its competitors. This is 34% below median its historical median of 22.84. Over the past decade, Becton Dickinson's EBITDA Margin % has ranged from 19.02 to 24.13. According to the industry distribution chart, Becton Dickinson ranks #170 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 20.8%.
Is Becton Dickinson's EBITDA Margin % too high?
Becton Dickinson's current EBITDA Margin % of 15.02% is 34% below median its 10-year median of 22.84. Over the past 10 years, this metric has ranged from a low of 19.02 to a high of 24.13. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Becton Dickinson's value of 15.02% is 100.9% above this industry median. Based on the distribution chart, Becton Dickinson ranks #170 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Becton Dickinson has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Becton Dickinson's EBITDA Margin % compare to MDLN and RMD?
According to the Medical Devices & Instruments industry distribution chart, Becton Dickinson ranks #170 out of 816 companies for EBITDA Margin %. This places Becton Dickinson in the top 21% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Becton Dickinson's value of 15.02% is 100.9% above this benchmark. Historically, Becton Dickinson's own EBITDA Margin % has ranged from 19.02 to 24.13 over the past decade. While the company's 10-year median is 22.84 vs. the industry median of 7.48, Becton Dickinson has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Becton Dickinson's current EBITDA Margin % of 15.02% is 100.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Becton Dickinson and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Becton Dickinson's current EBITDA Margin % is 15.02%, which is 34% below median its own 10-year median of 22.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Becton Dickinson stock overvalued right now?
Based on GuruFocus' analysis, Becton Dickinson (BDX) is currently considered Modestly Undervalued. The stock's GF Value™ is $191.05, compared to a current price of $151.38 — trading 20.8% below its estimated fair value. The current EBITDA Margin % is 15.02%, which is 34% below median its 10-year median of 22.84 and 100.9% above the Medical Devices & Instruments industry median of 7.48. Becton Dickinson's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Becton Dickinson (BDX), the current EBITDA Margin % is 15.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Becton Dickinson (BDX) Overvalued in 2026?
Based on GuruFocus' analysis, Becton Dickinson stock appears to be undervalued.
The current stock price of $151.38 is trading 20.8% below its estimated GF Value™ of $191.05.
GuruFocus considers Becton Dickinson to be Modestly Undervalued.
Key valuation signals for BDX:
EBITDA Margin %: 15.02% (34% below median its 10-year median of 22.84)
GF Value™: $191.05 vs. price of $151.38 (20.8% below fair value)
Industry Position: 100.9% above the Medical Devices & Instruments median (#170 of 816)
No single metric tells the full story. See the BDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
76GF Score
Get the complete analysis for BDX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BDX has been successfully added to your 
